文献速递胸部肿瘤

解码非小细胞肺癌中EGFR常见、复合及罕见突变的临床与分子特征:简要报告

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report.
PubMed 文献 · J Thorac Oncol · 2024-12-16

该研究分析19,163例肺腺癌患者(5,212例EGFR突变)的多队列基因组数据,比较常见、罕见及复合EGFR突变的临床与分子特征。罕见突变占EGFR变异的8.9%,多见于吸烟者,与烟草相关突变特征、KRAS和TP53共突变及高肿瘤突变负荷相关。罕见突变患者TKI治疗中位时间(4.1个月)短于常见和复合突变患者(分别为10.9和12.4个月)。

要点

  • 罕见EGFR突变占EGFR变异肺腺癌的8.9%,在吸烟者中更常见。
  • 罕见突变肿瘤有更高EGFR扩增、KRAS和TP53突变率及更高肿瘤突变负荷。
  • 罕见突变患者TKI治疗中位时间4.1个月,短于常见突变10.9个月和复合突变12.4个月。

核心结论

  • 肺腺癌EGFR突变类别存在临床和分子异质性,罕见突变与吸烟及KRAS、TP53共突变相关。
  • 包括下一代测序在内的全面分子检测对识别罕见突变和指导治疗决策至关重要。
  • 鉴于罕见EGFR突变亚组与烟草相关分子特征和高肿瘤突变负荷相关,需进一步研究免疫治疗在该亚组中的作用。

研究设计与样本

  • 分析19,163例肺腺癌患者的多队列基因组数据集,其中5,212例携带EGFR突变。
  • 将突变分为常见、罕见和复合类别,评估患者人口学、突变特征和肿瘤微环境因素,重点关注吸烟状态及KRAS和TP53共存改变。
  • 以治疗时间作为TKI疗效的替代指标分析治疗结局。

主要发现

  • 罕见EGFR突变占EGFR变异病例的8.9%,在吸烟者中显著更常见,并与烟草相关突变特征相关。
  • 与常见EGFR突变病例相比,罕见EGFR突变肿瘤报告更高的EGFR扩增、KRAS和TP53突变率。
  • 罕见突变还表现出更高的肿瘤突变负荷和与细胞周期活动相关的独特转录谱。
  • 罕见突变患者TKI治疗中位时间(4.1个月)明显短于常见突变(10.9个月)和复合突变(12.4个月)患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: EGFR mutations are key oncogenic drivers in lung adenocarcinoma (LUAD), predominantly affecting Asian, nonsmoking, and female populations. Although common mutations, such as exon 19 deletions and L858R, respond well to tyrosine kinase inhibitors (TKIs), uncommon EGFR mutations and compound variants exhibit variable treatment responses. This study aims to compare clinical characteristics and molecular profiles of patients with common, uncommon, and compound EGFR mutations, assessing their implications for therapy outcomes. METHODS: We analyzed a multi-cohort genomic dataset of 19,163 patients with LUAD (5,212 with EGFR mutations), categorizing mutations into common, uncommon, and compound classes. Patient demographics, mutational signatures, and tumor microenvironment factors were assessed, with particular attention to smoking status and concomitant alterations in KRAS and TP53. Treatment outcomes were analyzed by time under treatment as a surrogate measure of TKI efficacy. RESULTS: Uncommon EGFR mutations, comprising 8.9% of EGFR-altered cases, were significantly more frequent among smokers and associated with tobacco-related mutational signatures. Compared with common EGFR-mutant cases, tumors harboring uncommon EGFR mutations reported higher rates of EGFR amplifications, KRAS, and TP53 mutations. Uncommon mutations also exhibited higher tumor mutational burden and distinct transcriptional profiles linked to cell cycle activity. Median time on treatment with TKIs was notably shorter in patients with uncommon mutations (4.1 mo) than those with common and compound mutations (10.9 mo and 12.4 mo, respectively). CONCLUSIONS: This study underscores the clinical and molecular heterogeneity of EGFR mutation classes in LUAD, highlighting the unique profile of uncommon mutations, particularly their association with smoking and co-mutations in KRAS and TP53. Comprehensive molecular testing, including next-generation sequencing, is crucial to identify these uncommon mutations and inform therapeutic decisions. Further investigation into the role of immunotherapy in patients with uncommon EGFR mutations is warranted given the tobacco-related molecular signatures and high tumor mutational burden associated with this subgroup.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Tavernari D, Borgeaud M, Liu X, et al. Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report. J Thorac Oncol. 2024. PMID: 39694414. doi:10.1016/j.jtho.2024.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。